Prostaglandin Associated Periorbitopathy in Japanese Lantanoprost Users.

Prostaglandin Associated Periorbitopathy in Japanese Lantanoprost Users. - Prostaglandin Associated Periorbitopathy in Japanese Lantanoprost Users.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014127

Enrollment

Registered

2014-05-31

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects with glaucoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: They were all prostaglandin F2a naive patients before starting treatment, and at least 12mo follow up periods after prescribing latanoprost.

Exclusion criteria

Exclusion criteria: None of the subjects had a previous history of glaucoma surgery or neuro-ophthalmological disease and any ocular surgery during the follow up.

Design outcomes

Primary

Measure	Time frame
Upper eyelid ptosis, deepening of the upper eyelid sulcus (DUES), flattening the lower eyelid bags, inferior scleral show) associated PAP	—

Secondary

Measure	Time frame
Supplemental side effect around eyelids (trichiasis, poliosis and eyelid pigmentation)	—

Countries

Japan

Contacts

Public ContactShunsuke Nakakura

Saneikai Tsukazaki Hospital ophthalmology

shunsukenakakura@yahoo.co.jp079-272-8555

Outcome results